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The natural history of abdominal aortic
aneurysms is enlargement and rupture.1 The preva-
lence of abdominal aortic aneurysm has increased in
the past 30 years,2 and up to 50% of patients with
untreated aneurysms will die of rupture in a 5-year
period.3-5 Open surgical repair is effective in the pre-
vention of rupture and can be performed with 2% to
5% mortality rates in most experiences.6-9 However,
patients with aneurysms are generally elderly and
often have significant associated comorbid medical
conditions that increase the operative risks.
Furthermore, open surgical repair is associated with
significant morbidity rates in 15% to 30% of
patients.9,10 Because of the considerable risks associ-
ated with open surgical repair of aortic aneurysms,
less-invasive treatment options with endoluminal
stent grafts are gaining favor.
Endovascular stent graft repair of abdominal aor-
tic aneurysms offers the possibility of reduction of the
perioperative risk of aneurysm repair. Since the first
endovascular aneurysm exclusion by Parodi et al11 in
1991, a number of devices and strategies have been
developed and evaluated.12-20 Successful aneurysm
exclusion has been achieved in 50% to 90% of
cases,12-20 but a number of problems have been iden-
tified, including vessel perforation, the inability to seal
the aneurysm, the inability to advance the device
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through the iliac artery, and the need for conversion
of the procedure to open surgical repair.15 Numerous
reports describe an ever-increasing number of experi-
ences with endovascular stent grafting of aneurysms,
but most lack a surgical control group. Retrospective
reviews that compare endoluminal aneurysm repair
with concurrent open surgical repair have revealed no
differences in perioperative mortality rates and short-
er hospital stays with endoluminal repair.21
We report the results of a prospective, nonran-
domized, multicenter controlled clinical trial that
compared open surgical repair with endovascular
repair of infrarenal abdominal aortic aneurysms. The
clinical trial compared a prospectively defined surgi-
cal control group with the initial phase I and phase
II clinical experiences with the Medtronic AneuRx
stent graft system (Sunnyvale, Calif). Thus, this
report includes the learning curve involved with the
use of this new endovascular approach for the treat-
ment of aortic aneurysms.
METHODS
Endovascular prosthesis. The Medtronic
AneuRx stent graft is a modular bifurcated stent
graft system. The modular stent graft components
consist of a thin-walled, noncrimped woven poly-
ester graft supported with a nickel-titanium alloy
(Nitinol) exoskeleton. The primary components are
a main bifurcated segment and a contralateral iliac
limb. Additional modular components include aortic
and iliac extender cuffs (Fig 1). The components of
the self-expanding stent graft are contained in a
delivery sheath and are introduced through a retro-
grade approach with fluoroscopic imaging control
through small femoral arteriotomies. The bifurcated
device is available in aortic diameter sizes from 20 to
28 mm and iliac diameter sizes from 12 to 16 mm.
Length adjustments can be made with proximal and
distal extender cuffs.19-20,22
Clinical study design. This clinical investiga-
tion was undertaken to evaluate the safety and effec-
tiveness of the Medtronic AneuRx stent graft system
in the treatment of infrarenal abdominal aortic
aneurysms and to compare its safety and effectiveness
with the medical standard of care, namely open sur-
gical repair. The study design consisted of a phase I
feasibility study (four study sites) to show an ade-
quate level of safety and effectiveness to justify expan-
sion to a phase II controlled study according to Food
and Drug Administration guidelines. The phase II
clinical study expanded the number of investigation-
al study sites to 12 and compared the stent graft
treatment with standard surgical repair. Each study
site received approval and oversight from its
Institutional Review Board (See Appendix).
Patient selection. Patients with nonruptured
infrarenal aortic and aortoiliac aneurysms were candi-
dates for the trial if the aneurysm met one of the fol-
lowing criteria: larger than 5 cm in diameter, between
4 and 5 cm in diameter with a documented increase
of 0.5 cm in the past 6 months, twice the diameter of
the infrarenal neck, or saccular. Additional require-
ments included an infrarenal neck between 18 and 26
mm in diameter with a minimum length below the
most inferior renal artery of 1.0 cm without excessive
tortuosity. Iliac artery requirements included a lumen
caliber that allowed access with a 21F (outside diam-
eter) delivery catheter on one side and a 16F sheath
on the contralateral side with a maximum distal iliac
artery diameter of 16 mm.
Exclusion criteria included the following condi-
tions: age less than 18 years; acute renal failure;
pregnancy or lactation; connective tissue disease;
active systemic infection; hypercoagulability; a trau-
matic aneurysm; problems that prevented follow-up;
life expectancy of less than 1 year; the inability to
give informed consent; an acutely ruptured or leak-
Fig 1. Modular design of AneuRx stent graft system.
Primary modular components are main bifurcated segment
and contralateral iliac limb. Modular proximal (aortic) and
distal (iliac) extender cuffs allow length adjustment.
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ing aneurysm; a suprarenal, thoracic, or inflammato-
ry aneurysm; and morbid obesity that limited x-ray
imaging capability.
Before entering the study, each patient under-
went evaluation with a contrast-infused computed
tomographic (CT) scan and contrast angiography to
evaluate the morphologic features of the aneurysm
and visceral branch vessels. Some patients also
underwent magnetic resonance angiography and
intravascular ultrasound scan imaging, particularly in
the cases in which limitation of contrast infusion was
indicated. All the patients were operative candidates,
with American Society of Anesthesiologists (ASA)
risk classifications I to IV, signed informed consent,
and agreements to 1-year follow-up periods.
Surgical controls. Patients and referring doc-
tors often decline open surgical repair if endovascular
repair is a treatment option, which could potentially
result in unmatched treatment groups. Therefore, in
an effort to match the surgical and endovascular
study groups, the patients for surgical control were
prospectively enrolled at each of the 12 study sites
before the enrollment of the patients in the endovas-
cular treatment group. The entry criteria were the
same for the patients for surgical control and the
patients for stent grafting. The patients who met 
the study inclusion and exclusion criteria underwent
aortic imaging procedures. Those who met the study
criteria for stent graft repair were provided with
informed consent and were invited to participate in
the study. Those patients who signed the informed
consent and agreed to the follow-up protocol were
accepted into the surgical control group and under-
went open surgical repair. After the surgeons at a
study site had operated on five patients for surgical
control, the site was authorized to begin endovascu-
lar stent graft treatment with the same patient entry
criteria. Follow-up was required at the same intervals
for both the surgical and stent graft groups and was
continued for at least 1 year.
Surgical and endovascular treatment proce-
dure. The patients in the surgical control group
underwent operative repair of the aneurysm with
general anesthesia and with standard open surgical
techniques. Either a transperitoneal or a retroperi-
toneal approach was used to expose the aneurysm,
and a prosthetic tube or bifurcated graft was sutured
in place to exclude the aneurysm. The endovascular
stent graft procedures were performed in the oper-
ating room or the endovascular procedure room
with general or epidural anesthesia and femoral
artery exposure through groin incisions. A team
approach with a vascular surgeon and an interven-
tional radiologist working together was used. The
intraoperative imaging was performed with fixed or
portable fluoroscopy, intraoperative angiography,
and intravascular ultrasound scanning. All 250
patients in the two arms of the study underwent
treatment during an 18-month period that began in
May 1996 and ended in November 1997.
Follow-up evaluation. Before hospital dis-
charge, abdominal x-rays and spiral CT angiography
were performed in patients with stent grafts to doc-
ument the position and patency of the stent graft
and to evaluate aneurysm size, branch vessel paten-
cy, and the presence or absence of contrast fill of the
aneurysm, or endoleak (Fig 2). All the imaging stud-
ies were evaluated locally at each study site and at an
independent central core laboratory. After hospital
discharge, all the patients in both the surgical and
stent graft groups were evaluated at 1 month, 6
months, and 1 year. The patients with stent grafts
underwent imaging with color duplex ultrasound
scan or contrast CT scan at 1 month and contrast
CT imaging at 6 and 12 months (Fig 3).
Statistical analysis. The results are expressed as
the mean ± the standard deviation. Differences
between the groups were evaluated with c 2 test and
two-tailed Student t test. Differences were reported
as significant if the P value was less than .05.
RESULTS
Phase I stent graft feasibility trial. Phase I of
the trial included 40 patients with infrarenal abdomi-
nal aortic aneurysms (5.7 ± 0.8 cm) who underwent
treatment at four study centers. The AneuRx stent
graft was successfully deployed in all 40 patients, with
successful exclusion of the aneurysm. There were no
endoleaks and no surgical conversions. Three patients
(7.5%) died in the 30-day perioperative period—two
from chronic obstructive pulmonary disease and res-
piratory failure, and one from sepsis as a result of a
gangrenous gallbladder. There were four major com-
plications (10%): two patients had iliac limb throm-
bosis and required femoral-femoral bypass grafting,
one patient required common femoral endarterecto-
my for focal stenosis, and one patient had cardiac
arrhythmia. There were no device related deaths and
no aneurysm ruptures or late surgical conversions.
Phase II clinical trial. Phase II of the trial
included 150 patients who underwent treatment
with the stent graft system at 12 study centers. The
initial experience with the endovascular procedure in
eight study centers occurred during phase II. The
number of patients who underwent treatment at
each center ranged from 1 to 26, with a mean of 13.
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There was no difference in outcome between the
three centers that contributed the largest number of
patients (40% of the total) and the remaining nine
centers. The periprocedural (30-day) mortality rate
was lower (2 of 150, 1.3%) in phase II than in phase
I (3 of 40, 7.5%; P < .05). Procedure time, blood
loss, and intensive care unit (ICU) time were lower
in phase II than in phase I (P < .01), which reflects
improvements in the stent graft procedure gained
during phase I. There were no other significant dif-
ferences between the two phases of the trial.
Therefore, the results of phase I and phase II
endovascular treatment groups are combined as the
stent graft group. The first 190 patients who under-
went treatment in the United States with the
AneuRx stent graft system, including the initial
learning curve at each site, are thus compared with
the 60 patients who underwent treatment with open
surgery to comprise this report.
Patient characteristics. The characteristics of
the patient populations for surgery and stent graft-
ing are listed in Table I. Patients in both groups had
multiple risk factors and comorbidities, but there
were no significant differences between the groups.
The ASA operative risk classification tended to be
higher in the patients for stent grafts, with 26% in
ASA IV and 9% in ASA I and II, as compared with
the surgery group, which had 17% in ASA IV and
18% in ASA I and II. However, these differences
were not statistically significant (P = .07). There was
no difference in aneurysm size between the surgery
and stent graft groups, and all the patients met the
morphologic entry criteria for stent grafting.
Primary procedure results. Open surgical
repair of the abdominal aortic aneurysm was suc-
cessfully accomplished in all 60 patients for surgery
(100%). The stent graft was successfully deployed in
185 of 190 patients for stent grafts (97%; Table II).
In four patients for stent grafts, the aorta could not
be accessed through the iliac artery and the proce-
dure was terminated. These four patients declined
open surgical repair and returned to their referring
Fig 2. Cross-sectional images of contrast infused spiral computed tomographic scans of 67-
year-old man with 7.3-cm abdominal aortic aneurysm. A, Preoperative computed tomograph-
ic scan shows 7.3-cm abdominal aortic aneurysm with little mural thrombus. B, One month
after stent graft placement, aneurysm is fully excluded with no endoleak and no change in
aneurysm size. C, After 6 months, aneurysm has decreased in size to 6.9 cm. D, After 1 year,
aneurysm has decreased in size to 6.2 cm.
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physician after a 30-day follow-up period. One
patient for stent graft had a myocardial infarction on
induction of anesthesia. The procedure was can-
celled, and the patient has declined a subsequent
procedure. There were no surgical conversions to
open aneurysm repair in the stent graft group, and
no patient has had a ruptured aneurysm.
There was no difference in anesthesia time or pro-
cedure time between the two groups. The patients
who underwent treatment with stent grafts had 60%
less blood loss as compared with the patients who
underwent open surgery (P < .001), and these patients
required 80% less blood transfusions (P < .05). The
blood loss in the patients for stent grafts was primarily
caused by leakage from catheters, sheaths, and hemo-
static values. Only 12% of the patients in the stent graft
group underwent a blood transfusion as compared
with 40% in the surgery group (P < .001). There was
a marked reduction in the time to extubation, dis-
charge from the ICU, ambulation without assistance,
and eating a regular diet in the stent graft group as
compared with the surgery group (Table II). The hos-
pital length of stay was reduced by two thirds in the
stent graft group, from 9.4 days to 3.4 days (P < .001).
Mortality rates. All the patients survived open
surgical repair; the operative mortality rate in the
surgery group was 0%. Five patients (2.6%) died in
the stent graft group. There was no significant dif-
ference in the mortality rates between the two
groups (Table III). Three of the 40 patients in phase
I died during the 30-day perioperative period—two
from chronic obstructive pulmonary disease and res-
piratory failure, and one from sepsis as a result of a
gangrenous gallbladder. Two of the 150 patients in
phase II died during the 30-day perioperative peri-
od: one from colon ischemia and multisystem organ
failure, and one as a result of myocardial infarction.
The mortality rate was significantly lower in phase II
(1.3%) as compared with phase I (7.5%; P < .05).
The youngest patient in the study was in phase II.
This patient was 45 years old, had no cardiac symp-
toms, and had negative preoperative, noninvasive
evaluation results by a cardiologist. The patient was
discharged 3 days after successful stent graft repair.
Twenty days later, the patient had a myocardial
infarction, underwent coronary angiography, and
was discovered to have a 95% left main coronary
stenosis—he died during interventional efforts to
Table I. Patient characteristics
Risk factors/comorbidities Surgery (n = 60) Stent grafting (n = 190) P value
Mean age (years) 69 ± 7 73 ± 8 NS
Age range (years) 49 to 97 45 to 91 NS
Male gender 85% 90% NS
Family history of AAA 15% 8% NS
Smoking 83% 85% NS
COPD 33% 23% NS
Hypertension 60% 69% NS
Coronary artery disease 87% 84% NS
History of MI 25% 34% NS
CABG/PTCA 55% 45% NS
Stroke/TIA 15% 19% NS
Peripheral vascular disease 25% 18% NS
Diabetes mellitus 10% 7% NS
Renal failure 5% 4% NS
Obesity 15% 21% NS
Alcohol use 5% 5% NS
Carcinoma 23% 21% NS
ASA risk category
I to II 18% 9%
III 65% 65%
IV 17% 26% NS (P = .07)
Aneurysm size (cm) 5.6 ± 1.1 5.6 ± 0.9 NS
Range of size (cm) 3.5 to 10.0 3.3 to 9.0 NS
AAA, Abdominal aortic aneurysms; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; CABG, coronary artery
bypass grafting; PTCA, percutaneous transluminal coronary angioplasty; TIA, transient ischemic attack; ASA, American Society of
Anesthesiologists.
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treat the coronary lesion. The oldest patient in the
study, who was 97 years old, underwent open
surgery, had no complications and was alive and well
1 year later.
Morbidity rates. Complications were markedly
reduced in the stent graft group as compared with
the surgery group. Major morbidity was defined as
any condition that necessitated a reoperation or a
secondary treatment procedure in the operating
room or angiography suite, myocardial infarction,
major arrhythmia, stroke, renal failure that necessi-
tated dialysis, or another medical condition that pro-
longed hospital stay more than 7 days in the surgery
group or more than 5 days in the stent graft group.
Major morbidity occurred in 23% of the patients
who underwent open surgery, whereas only 12% of
Table II. Primary procedure results
Surgery (n = 60) Stent grafting (n = 190) P value
Procedure success rate 100% 97% NS
Anesthesia time (hours) 4.9 ± 1.8 4.5 ± 1.6 NS
Procedure time (hours) 3.6 ± 1.6 3.1 ± 1.3 NS
Blood loss (mL) 1596 ± 1432 641 ± 636. <.001
Blood replaced (units) 1.6 ± 3.8 0.3 ± 1.2 <.05
Patients requiring transfusion 40% 12% <.001
Extubation time (days) 0.9 ± 2.3 0.1 ± 0.3 <.05
ICU days 2.5 ± 3.1 0.9 ± 1.2 <.05
Ambulate without assistance (days) 4.0 ± 4.8 1.5 ± 1.2 <.001
Regular diet (days) 5.1 ± 2.5 1.4 ± 0.9 <.001
Hospital days (LOS) 9.4 ± 10.8 3.4 ± 2.7 <.001
Hospital days (range) 3 to 72 1 to 20
ICU, Intensive care unit; LOS, length of stay.
Fig 3. Shaded surface of three-dimensional reconstruction of spiral computed tomographic
scan showing: A, a 6.2-cm infrarenal aortic aneurysm in a 65-year-old man; and B, 1 year later,
complete exclusion of aneurysm by stent graft. Aneurysm has decreased in size to 5.2 cm (not
seen in this image).
the patients who underwent stent grafting had a
major complication (P = .03; Table III). Major mor-
bidity included surgical and medical complications.
The surgical complications included the need for
reoperation in 12% of the patients who underwent
open aneurysm repair, with 5% needing more than
one reoperation. Of the patients who underwent
stent graft repair, 9% had reoperations or secondary
procedures and none needed more than one reoper-
ation. Major medical complications were more com-
mon in the surgery group (12%) as compared with
the stent graft group (3%; P = .009).
Minor morbidity was defined as complicating
events that did not prolong hospital stay greater
than 7 days in the surgery group or greater than 5
days in the stent graft group. This included, in the
surgery group, two patients with leg numbness and
weakness, one patient with pneumonia, and one
patient with a urinary tract infection. In the stent
graft group, this included two patients with superfi-
cial groin wound infections, two patients with minor
toe embolizations that did not necessitate treatment,
one patient with femoral neuropathy, one patient
with atrial fibrillation, and three patients with mild-
ly elevated creatinine levels. There was no difference
in minor morbidity rates between the two groups
(Table III).
Combined morbidity/mortality rates. The
major morbidity/mortality rate in the open surgery
group (23%) was not statistically different from that
of the stent graft group (14%). The total morbidi-
ty/mortality rate in the open surgery group (30%)
was not significantly different from that of the stent
graft group (19%).
Major morbidity. The major complications are
summarized in Table IV. There was no difference
between the two groups in the number of patients
with complications that necessitated reoperation.
However, there was a significant difference in the
magnitude of the complications between the two
groups. In the surgery group, six patients (10%)
required major abdominal operations—two for
colon ischemia, two for postoperative bleeding, one
for wound dehiscence, and one for infection. Three
of the six patients required more than one major
reoperation. In the stent graft group, two patients
(1%) required abdominal operation—one for colon
ischemia as a result of inferior mesenteric artery
(IMA) and internal iliac occlusion, and one for
bleeding as a result of a guide wire that was intro-
duced through the brachial artery and perforated a
superior mesenteric artery branch. This difference
was highly significant (P < .001). There was no dif-
ference between the groups in the requirement for
groin or peripheral reoperation. One patient in the
surgery group underwent thrombectomy for graft
limb thrombosis. In the stent graft group, four
patients required reoperation to repair endoleaks,
two patients to correct graft limb thrombosis, three
patients to correct femoral artery stenosis, two
patients to repair femoral artery occlusion, one
patient to repair a brachial arteriovenous fistula, and
one patient to release an entrapped femoral cuta-
neous nerve. One patient in the stent graft group fell
and sustained a hip fracture, which necessitated sur-
gical pinning. The mean hospital length of stay in
the patients for surgery who required reoperations
was prolonged considerably to 31 days (P < .05),
whereas the mean hospital stay in the patients with
stent grafts who required reoperation was only pro-
longed to 7 days, which was no different from the
mean length of stay of the patients for surgery.
Medical complications were more frequent in the
surgery group as compared with the stent graft
group (P < .01). The patients with major complica-
tions had a significant increase in hospital length of
stay in both the surgery and the stent graft groups as
compared with those patients without complications
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Table III. Mortality and morbidity rates (30 days)*
Surgery (n = 60) Stent grafting (n = 190)
Patients % Patients % P value
Mortality 0 0 5 3 NS
Device-related mortality 0 0 0 0 NS
Major morbidity 14 23 22 12 <.05
Surgical complications 7 12 16 9 NS
Medical complications 7 12 6 3 <.01
Minor morbidity 4 7 10 5 NS
*Each patient was counted once with the most severe event recorded.
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(Table IV). The hospital length of stay in the surgery
group was at least twice as long as in the stent graft
group, whether or not there was a complication.
Procedural success rate. Primary technical suc-
cess was defined in accord with the Society for
Vascular Surgery and the International Society for
Cardiovascular Surgery (SVS/ISCVS) reporting
standards for lower extremity arterial endovascular
procedures24 and adapted for endovascular aortic
aneurysm repair. Primary technical success was on
the basis of intent to treat and included all patients
who consented to enter either the surgical or stent
graft group. The patients who survived the proce-
dure and had an excluded aneurysm with a patent
graft without significant kinks, twists, or obstruction
at the time of discharge and without need for a sec-
ondary procedure were considered to be primary
technical successes. The primary technical success
rate in the surgery group was 98%. One patient had
a graft limb thrombosis and required thrombecto-
my. The primary technical success rate in the stent
graft group was 77% (P < .01). Five patients died,
and 39 had endoleaks on CT scan at 24 to 48 hours
(Table V). However, the SVS/ISCVS reporting
guidelines do not fully take into consideration the
complications that may accompany surgical and
stent graft procedures. Therefore, a primary proce-
dure success rate was defined.
Primary procedural success was defined as
patients who were alive at 30 days with a patent
graft, excluded aneurysm (no endoleak), no need for
reoperation or secondary procedure, and no major
complication. Primary procedural success in the
surgery group was 77% (46 of 60 patients) and in
the stent graft group was 78% (148 of 190 patients).
There was no difference in the primary procedural
success rate between the two groups (Table V).
Secondary procedural success was defined as
patients who were alive and home from the hospital
at 30 days with an excluded aneurysm and a patent
Table IV. Major complications*
Surgery (n = 60) Stent grafting (n = 190)
Patients % Patients % P value
Surgical complications 7 12 16 9 NS
Major abdominal 6 10 2 1 <.001
Groin/peripheral 1 2 13 7 NS
Other — — 1 1 NS
Hospital LOS (days) 31 ± 22 7 ± 7 <.05
Medical complications 7 12 6 3 <.01
MI/arrhythmia 3 5 4 2 NS
CVA 2 3 1 1 NS
Other 2 3 1 1 NS
Hospital LOS (days) 11 ± 7 9 ± 6 NS
Hospital LOS with complications 21 ± 18 8 ± 7 <.05
(days)
Hospital LOS without complications 6 ± 2 3 ± 2 <.001
(days)
*Each patient counted once with most severe event recorded.
LOS, Length of stay; MI, myocardial infarction; CVA, cardiovascular accident.
Table V. Procedure success
Surgery (n = 60) Stent graft (n = 190)
Patients % Patients % P value
Primary technical success* 59 98 146 77 <.01
Primary procedural success† 46 77 148 78 NS
Secondary procedural success‡ 57 95 169 89 NS
Aneurysm excluded at 30 days 60 100 164 91 <.05
*No death with complete exclusion of the aneurysm with patent graft at discharge.
†Patient alive, aneurysm excluded, graft patent, no major morbidity or secondary procedure at 30 days.
‡Patient alive, home from hospital, aneurysm excluded, graft patent at 30 days.
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graft. This measure of success excludes complica-
tions and includes the benefits of secondary proce-
dures. Secondary procedural success in the surgery
group was 95%; three patients were still in the hos-
pital as a result of complications. Secondary proce-
dural success in the stent graft group was 89%; five
patients had died, and 16 had endoleaks. There was
no statistical difference in the secondary procedural
success rate between the groups.
The aneurysm exclusion rate at 30 days in sur-
viving patients who had undergone stent graft place-
ment was 91%. There were 180 surviving patients
with stent grafts, and 16 had endoleaks at 1 month.
The aneurysm exclusion rate in patients who under-
went treatmentd with open surgery was 100%.
Stent graft procedure—adverse events. Adverse
events that were related to the stent graft procedure
are summarized in Table VI. Failure to gain 21F deliv-
ery catheter or 22F access sheath to the aorta through
the iliac artery occurred in four patients (2%) and
resulted in abandoning the stent graft procedure.
External iliac artery dissection occurred in four
patients (2%) as a result of sheath advancement and
necessitated repair during the primary procedure with
an uncovered stent, endarterectomy, or an interposi-
tion vascular graft. There has been no limb ischemia as
a result of this occurrence. Minor embolization was
noted in three patients: two patients had evidence of
embolization to the toes with no tissue loss and no
intervention, and one patient was noted to have a seg-
mental renal infarct on postoperative CT scan. There
has been no major embolization that necessitated
treatment. Branch vessel occlusion occurred in nine
patients; eight internal iliac arteries and one renal
artery. Two internal iliac arteries were intentionally
occluded because of internal iliac aneurysm, and six
internal iliac arteries were unintentionally occluded.
Most of these patients had mild, transient hip and but-
tock claudication that was not disabling. One renal
artery was occluded with a proximal extender cuff.
This patient is asymptomatic and normotensive and
has a normal creatinine level. Colon ischemia has
occurred in two patients: one patient had internal iliac
occlusion and died of colon ischemia and multisystem
organ failure, and the other had transient but pro-
longed intraoperative internal iliac obstruction while
the introducer sheath was in place and had mild post-
operative hematochezia that necessitated supportive
treatment only with full recovery. Transient creatinine
level elevation greater than 2.0 mg/dL occurred in
seven patients (4%). All seven patients recovered, and
none have required dialysis. Six patients (3%) have
required subsequent groin procedures to correct
femoral artery occlusion or stenosis. Two patients had
femoral neuropathy, one of whom required groin
wound exploration and release of nerve entrapment
caused by a suture used to close the groin incision.
Graft patency. Graft limb thrombosis has
occurred in five patients (3%) with stent grafts and in
one patient (2%) for surgery. Four patients with stent
graft have undergone femoral-femoral bypass graft-
ing: two procedures occurred early in phase I in the
periprocedural period, one occurred at 2 months, and
one occurred at 6 months (Table VI). One patient
with stent graft underwent graft limb thrombectomy
at 3 months, and one patient for surgery underwent
graft limb thrombectomy in the periprocedure peri-
od. There has been no limb loss related to graft limb
Table VI. Adverse events related to stent graft
procedure
Patients %
Failure to access iliac artery 4 2
Iliac artery dissection 4 2
Embolization, major 0 0
Embolization, minor 3 2
Unintentional branch occlusion 7 4
(6 internal iliac, 1 renal)
Colon ischemia 2 1
Creatinine >2.0 (no dialysis) 7 4
Femoral artery repair 6 3
Femoral neuropathy 2 1
Iliac limb thrombosis 5 3
Table VIIA. Endoleaks after stent graft repair
Time of evaluation Number of endoleaks %
Before discharge 39/185 21
1 month after procedure 16/180 9
6 months after procedure 15/167 9
12 months after procedure 2/33* 6
*Two endoleaks at 12 months (one, aneurysm size has decreased
from 6.5 to 5.0 cm; one, sealed at 15 months).
Table VIIB. Secondary procedures for endoleaks
(11/185 = 6%)
Procedure No. Time after stent graft
Proximal extender cuff 5 Three before discharge
One at 8 months
One at 12 months
Distal extender cuff 5 Three before discharge
One at 2 months
One at 12 months
Lumbar artery coiling 1 One at 1 month
Total 11
thrombosis. One patient with stent graft who had a
diabetic foot infection has undergone above-knee
amputation with a patent stent graft during the fol-
low-up period. The primary stent graft patency rate at
6 months is 97%, and the primary surgical graft paten-
cy rate at 6 months is 98%. There is no difference
between the groups in graft patency rate.
Endoleaks. Immediately after stent graft deploy-
ment, intraoperative angiograms were performed to
assess aneurysm exclusion. Endoleaks were reported in
only 6% of the completion angiograms, and this study
was not believed to be a reliable measure of the
endoleak rate. All the patients in the stent graft group
underwent contrast infused CT scanning before dis-
charge (usually at 24 to 48 hours) to document the
presence or the absence of an endoleak (Table VII).
The presence or the absence of contrast within the
aneurysm sac was recorded, and the source of the
endoleak was localized when possible. Note was made
of proximal or distal attachment site endoleaks, graft
junction endoleaks, and lumbar or IMA branch flows.
A blush of contrast in the aneurysm sac with no iden-
tifiable source was classified as “transgraft flow.”
Endoleaks were identified in 39 of 185 patients (21%)
before hospital discharge. Of these, 10 were classified
as “transgraft flow” and all were sealed at 1 month.
Twelve were felt to be results of lumbar artery/IMA
branch flow. Of these, six were sealed at 1 month. One
lumbar artery was coiled, which resulted in the sealing
of the aneurysm. The remaining five continue to have
a persisting endoleak at 6 months. In seven patients,
endoleaks were identified at the proximal aortic sealing
point. Three patients were returned to the operating
room for the placement of a proximal extender cuff.
The four patients who were followed had a sealed
aneurysm at 6 months. However, two patients
returned at 8 and 12 months with recurrence of the
proximal endoleaks. These two patients also had evi-
dence of minor graft migration and each underwent
placement of a proximal extender cuff with immediate
sealing of the aneurysm. In 10 patients, the predis-
charge endoleak arose from the iliac limb either at its
junction to the main bifurcation stent body or at the
distal end. Three patients underwent treated with iliac
extender cuffs before discharge, and one patient
underwent treatment at 2 months with prompt sealing
of the aneurysm. Of the seven endoleaks that were
observed, five sealed at 1 month and two sealed at 2
and 5 months.
The endoleak rate at 1 month and at 6 months
was 9%. Of the 15 aneurysms with an endoleak at 6
months, nine are unchanged in size and five have
decreased in size. All 14 patients are clinically well
and asymptomatic. One patient with an endoleak at
6 months has an aneurysm that has increased in size
from 5 to 6.5 cm. He has multiple medical prob-
lems, with urinary tract sepsis and multisystem organ
failure, and is judged to be too ill to undergo further
evaluation. His aneurysm, though enlarged, remains
asymptomatic at 7 months.
At 12 months, two of 33 patients (6%) had an
endoleak documented on contrast spiral CT scanning.
In one patient, the aneurysm had decreased in size
from 6.5 to 5 cm. The other patient had no change in
the size of the aneurysm, and the small endoleak has
subsequently completely sealed at 15 months. There
have been no aneurysm ruptures and no surgical con-
versions among the 190 patients with stent grafts.
Stent graft migration. In three patients, migra-
tion of the stent graft has been identified during the 
1-year follow-up period. Each migration has been less
than a 1-cm displacement, and each has resulted in the
appearance of an endoleak and has been described pre-
viously in the endoleak section. Two migrations have
occurred in the proximal neck at 8 and 12 months and
have been corrected with a proximal extender cuff.
Both migrations had low placement of the stent graft
in the infrarenal neck at the original procedure and
probably could have been prevented with a proximal
extender cuff at the time of the original procedure.
The third migration resulted in the appearance of
endoleak at the iliac junction at 12 months and has
been corrected with an iliac extender cuff. The iliac
limb had been placed low in the junction segment of
the main bifurcation module during the original pro-
cedure in a patient with a tortuous iliac artery. A high-
er placement in the junction gate during the original
procedure might have prevented this occurrence.
Late mortality. Two patients (3%) in the
surgery group and 8 patients (4%) in the stent graft
group have died during the 1-year follow-up period.
The two deaths in the surgery group were caused by
myocardial infarction at 6 and 10 months. Four late
deaths occurred in patients in phase I—two as a
result of myocardial infarction at 3 and 6 months,
and two as a result of congestive heart failure at 8 and
11 months. Four late deaths occurred in patients
with stent grafts in phase II. Two of these deaths
were caused by myocardial infarction, one was caused
by lung cancer, and one was caused by complications
of colon cancer. There have been no aneurysm-relat-
ed deaths and no stent graft device–related deaths.
DISCUSSION
This prospective clinical trial compared the
results of endovascular stent graft repair of abdomi-
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nal aortic aneurysms with standard open surgery.
Patients in the surgical control group met all the cri-
teria for the stent graft trial and were prospectively
entered into the study before the initiation of
endovascular stent graft treatments in an effort to
prevent selection bias. There were no significant dif-
ferences between the groups in age, risk factors,
comorbidities, or aneurysm characteristics. However,
during the course of the study, as the availability of
the endovascular stent grafting became known, some
patients were referred by physicians for stent graft-
ing because they were considered to be too high risk
for open surgery. No additional patients were
entered into the surgical control group during the
course of the study. In particular, there were no
patients in the surgery group who were referred
because they were considered to be too high risk for
surgery. Thus, if there is an imbalance in the com-
position of the two study groups, it would be in the
direction of patients at higher risk being in the stent
graft group and potentially skewing the results in
favor of surgery. Although the stent graft group
tended to be somewhat older, there were no statisti-
cally significant differences between the groups and
adverse selection did not appear to significantly
influence the results.
The outcome of surgical repair of abdominal aor-
tic aneurysms is usually assessed primarily in terms of
perioperative mortality rates. The mortality rates for
the surgical repair of nonruptured aneurysms are
lowest in recent large, single center reports and
range from 0% to 4%,6-9,25 with a mean of 2%.
Multicenter reports generally have somewhat higher
mortality rates that range from 3% to 5%,26-28,30
with a mean of 4%,31 and population-based reports
have a mortality rate of approximately 7%.5,23,29,32
The mortality rate in this prospective multicenter
study was 0% in the surgery group and 2.6% in the
stent graft group. Both rates are well within the stan-
dard of care and below the mean operative mortali-
ty rate (4%) for recent multicenter reports on open
surgical repair31 and below the operative mortality
rate (5.6%) reported in concurrent surgical/endolu-
minal series.21 Most of the deaths in the stent graft
group (7.5%) occurred in phase I, and there was a
significant reduction in mortality rate (P < .05) in
phase II (1.3%), which perhaps was related to
improvements in the technical aspects of the proce-
dure as reflected in a significant reduction of opera-
tive time and blood loss in phase II as compared
with phase I. There was no significant difference in
late mortality rates between the two groups, and no
deaths could be attributed to the stent graft device.
Mortality rates, however, do not fully characterize
the debility that can result from the surgical repair of
aortic aneurysms. Complications that prolong hospi-
tal stay occur in 15% to 30% of patients who under-
go open surgery9,10 and were seen in 23% of the
patients in the surgical control group in this study.
Although complications also occurred in the stent
graft group, their frequency was reduced by one half
when compared with the surgery group. The com-
plication rate in the surgical group in this study is
higher than that experienced in some institutions
with open aneurysm repair. This is consistent with
the observation that multi-institutional trials report a
higher complication rate than reported by single cen-
ters.31 This difference was seen in the prospective
symptomatic33 and asymptomatic34 carotid artery
trials in which stroke/death rates were higher than
the rates reported in most published series of carotid
endarterectomy35 and highlights the importance of
comparison to a suitable control group.
Perhaps more important than the complication
rate was the striking reduction in the magnitude of
the complications experienced in the stent graft
group. Patients with stent grafts who required reop-
erations generally had relatively minor procedures
that were confined to the groin incision, and the
hospital length of stay in patients with stent grafts
with complications was no different from that of
patients for surgery without complications.
Thus, the major proposed advantages of this min-
imally invasive endovascular approach to aneurysm
repair were realized. The stent graft procedure itself
was less stressful to the patient than open surgery,
with far less blood loss, less need for blood transfu-
sion, earlier extubation, shorter ICU stays, earlier
ambulation, and earlier resumption of a regular diet.
The hospital length of stay was reduced by two
thirds, and patients were able to resume normal func-
tion shortly after discharge. Furthermore, there was a
marked reduction in major complication rates, espe-
cially in the need for major abdominal reoperations,
which were associated with the greatest morbidity
rates, ICU stays, hospital lengths of stay, and costs.
Although cost comparison between open surgical
repair and stent graft repair was not a part of this
investigation, it is possible that the reduction in com-
plication rates, ICU stay, the number and magnitude
of reoperations, and the length of hospital stay that
occurred in the stent graft group may result in sig-
nificant cost savings over open surgical repair.
The primary disadvantages of stent graft repair
are twofold. First, not all patients with infrarenal
aneurysms are candidates for the procedure.
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Although open surgical repair can readily accommo-
date patients with short or absent infrarenal necks,
severe tortuosity, accessory renal arteries, iliac
aneurysms and occlusions, and associated branch
vessel stenoses, these morphologic features may
exclude patients from stent graft repair. Thus, pre-
cise preoperative imaging is essential in the selection
of patients for the procedure. On the other hand,
some patients who are morphologically suited for
stent grafting and previously were denied surgical
repair because of high medical risk may become can-
didates for aneurysm repair with a stent graft.
The second and major disadvantage of stent
grafting is the uncertainty of the permanence of
aneurysm exclusion from the circulation. Continued
blood flow in the aneurysm sac (endoleak) exposes
the patient to an ongoing risk of aneurysm rupture.
Several authors have reported deaths from ruptured
aneurysms in patients who had previously under-
gone stent graft placement.36,37 However, the true
significance of endoleaks and whether the natural
history of aortic aneurysms is changed after endolu-
minal grafting is not yet known. Endoleaks can
occur early as a result of inadequate sealing of the
stent graft to the aortic neck or iliac arteries, flow
through the graft, defects in the graft fabric, or iliac
or IMA branch flow. Late leaks can occur from graft
migration or change in morphologic characteristics
and tortuosity of the aneurysm, aortic neck, or iliac
arteries. Continued close surveillance of patients
with stent grafts is necessary with repeated imaging
procedures. The modular extender cuffs available
with the AneuRx stent graft system allows subse-
quent procedures to correct endoleaks at junction
and sealing points both early and late. The early
(predischarge) endoleak rate was 21%, and the
endoleak rate at 1 and 6 months in this study was
9%. Three new endoleaks between 6 and 12 months
necessitated secondary treatments with extender
cuffs. The significance of an endoleak and branch
vessel flow in an aneurysm that is decreasing in size
is unknown.
Stent graft repair of aneuryms is associated with
a number of adverse events related to iliac artery
access by the large introducer sheath and the occa-
sional need to repair the common femoral artery at
the site of introduction of the sheath. This problem
is common to all current stent graft devices. Major
embolization, reported by others,37 was not seen in
this study. Three patients had minor embolization
that did not necessitate treatment: one to the kidney
was noted on follow-up CT scan, and two cases of
transient discoloration of the toes were documented.
Improvements in interventional technique and
sheath design likely account for the infrequent
occurrence of embolization.
Primary in-hospital technical success was defined in
accord with the SVS/ISCVS recommended reporting
standards for endovascular procedures.24 Complete
exclusion of the aneurysm from the circulation with no
death occurred in 77% of the 190 patients entered into
the stent graft trial. This is similar to the 85% primary
success rate (intention to treat not specified, one death
in the series) reported by Blum et al18 using the
Mialhe Stentor/Vanguard  (Boston Scientific, Nattick,
Mass) endoprosthesis and higher than the 48% 
primary technical success rate (46 patients, seven sur-
gical conversions, 17 endoleaks) reported in the
Endovascular Technologies (EVT) phase I controlled
clinical trial.12 However, primary technical success
does not take into consideration major complication
rates, which are prominent in the open surgical repair
of aortic aneurysms. To better compare the results of
endovascular repair with open surgical repair, we con-
sidered the major complication rate and defined pri-
mary 30-day procedural success. There was no differ-
ence in primary procedural success between surgery
(77%) and stent grafting (78%). Secondary procedural
success at 30 days considered the benefit of secondary
treatments in excluding the aneurysm and did not
count complications that resolved and allowed dis-
charge from the hospital in 30 days. The secondary
procedural success was 95% in surgery and 89% in
stent grafting, which was not statistically different.
Endoleaks have been reported in 14% to 44% of
patients with a variety of stent graft devices.13,16-18,37-
40 The 1-month endoleak rate of 9% in this series
appears to be lower; however, direct comparison trials
of various endovascular devices have not been per-
formed. The small number of patients (33) who were
observed at 1 year in this series does not allow reliable
assessment of the true long-term endoleak rate or
long-term outcome.
Surgical conversion has been reported in 2% to
16%13,16,19,41 of patients who undergo stent graft
repair. No patient in this series of endovascular stent
graft repair was converted to open repair. If the four
patients in whom iliac access was not possible had
undergone open repair, the surgical conversion rate
would have been 2%.
Longitudinal columar support and a flexible
endograft structure are provided by the AneuRx
stent graft device. This may account for the absence
of apparent longitudinal displacement in this series.
Changes in aortic endograft configuration have been
noted as the aneurysm morphology changes over
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time related to shrinkage of the aneurysm.42 For this
reason, longitudinal columar support combined
with a flexible endograft structure may be needed to
best accommodate to morphologic changes over
time and yet maintain fixation of the device. There
was no evidence of kinking of the endograft in asso-
ciation with the longitudinal shrinkage of the
aneurysm in our patient series. In this study, three
patients had mild lateral displacement and reappear-
ance of late endoleaks related to tortuosity and inad-
equate overlap and fixation.
The primary graft patency rate was no different
from the surgical control group and no different
from that reported by others.19 It should be borne
in mind that the results of stent grafting for
aneurysms may be device specific. We did not com-
pare the AneuRx device against other devices. Many
are undergoing development and clinical investiga-
tion. Each will need to be compared with a suitable
surgical control group.
In conclusion, endovascular stent graft repair of
infrarenal aortic aneurysms compared favorably with
open surgery with a significant reduction in patient
morbidity and a significant reduction in hospital stay.
The primary technical success rate was reduced in the
stent graft group primarily as a result of incomplete
aneurysm exclusion in 21% of patients at the time of
discharge. However, at 30 days, there was no differ-
ence in primary or secondary procedural success rate
and there was no difference in graft patency rate.
Endoleak rate at 1 month and 6 months was 9% and
at 12 months was 6%. Reliable long-term data are not
yet available. There have been no aneurysm ruptures
or conversions to open surgery.
We thank all the investigators and coordinators at each
of the study sites, the Medtronic AneuRx clinical study
support group, Robert C. Allen, MD, for onsite training
of investigators at new study sites, Bernardo D. Martinez,
MD, and Dustin Michaels for data analysis, and Rita R.
Wedell for preparation of the manuscript.
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Dr Michael S. Makaroun (Pittsburgh, Pa). Dr Zarins
and his colleagues have presented the results of a second
well-designed and well-controlled prospective trial com-
paring open surgical repair to stent graft repair of abdom-
inal aortic aneurysms. The outcomes support the conclu-
sion that, in a carefully selected group of patients with
aneurysmal disease, endovascular repair can achieve total
exclusion of the aneurysm with acceptable mortality, mor-
bidity, and failure rates. Short-term benefits include
reduced blood loss, decreased hospital stay, and an earlier
recovery. It is encouraging to note that the results of phase
II are better than phase I, despite initiating eight addi-
tional sites. This suggests that lessons learned with the
early experience of a new device can effectively be trans-
ferred to new users with the avoidance of a steep learning
curve at each site. This should be welcome news to every-
body in this audience.
Dr Zarins, I have a few questions for you.
We recently presented to the Society for Clinical
Vascular Surgery in March of this year our personal expe-
rience with the first 50 endovascular repairs that we per-
formed, and we compared them to our concurrent surgi-
cal patients. The main advantage of endovascular repair in
our experience was reduced blood loss and shorter hospi-
tal stay with no major difference in morbidity. In your
comparison to open procedures, medical complications
were notably reduced in the stent graft group. However,
the most severe medical complications that resulted in five
deaths in your stent graft group are not included in this
comparison. If these were included, would the benefits
still be apparent?
The numbers of reoperations in your open surgical
patients were significantly higher than in the stent graft
group. However, a 10% reoperation rate and a 5% multi-
ple reoperation rate is much higher than expected. Our
rate is less than 3%, and, in the EVT trial that was pre-
sented earlier today, the rate was around 1%. Was this a
chance occurrence because of a small sample size in the
open surgical group, or is this the experience with all open
cases at the 12 institutions in this study?
My second question relates to the endoleaks that
remain a major problem with this new technique and that
result in aneurysm enlargement and several reported rup-
tures. A third of your patients with a leak at 6 months had
a decreased aneurysm size, which is quite different from
many reports, including our own experience. How do you
explain this apparent regression of the aneurysm in the
face of the persistent leak? And do you feel comfortable
following patients expectantly when they have a leak and
no reduction in size of the aneurysm?
APPENDIX. CLINICAL INVESTIGATION SITES
Institution Principle investigator Coinvestigators Study coordinator
Stanford University Medical Center Christopher K. Zarins, MD Thomas J. Fogarty, MD Chris Corcoran, RN
(Stanford, Calif) Paul R. Cipriano, MD (650-498-7936)
Harbor–UCLA & VAMC Rodney A. White, MD Carlos E. Donayre, MD Linda Ephraim, RN
(Torrance, Calif) Irwin Walot, MD Abeline LoBue, RN
Rowena Buwalda, RN
(310-222-2704)
St Vincent’s Hospital Donald Schwarten, MD Marian F. McNamara, MD Sylvia Purichia, RN
(Indianapolis, Ind) (317-338-3534)
Surgical Care Associates Edward Kinney, MD None Shannon Buckman, RN
(Louisville, Ky) (502-897-5139)
Arizona Heart Institute Edward B. Diethrich, MD Julio A. Rodriguez-Lopez, MD Michelle Sagraves, RN
(Phoenix, Ariz) (602-266-2200, ext 4422)
SIU School of Medicine Kim J. Hodgson, MD Mark Mattos, MD Wendy Terry, RN
(Springfield, Ill) (217-785-2320)
Cleveland Clinic Foundation Timothy M. Sullivan, MD Bruce Gray, DO Mary Beth Childs, RN
(Cleveland, Ohio) (216-444-5086)
Sanger Clinic Robert M. Bersin, MD Robert Allen, MD Gale Schwartz, RN
(Charlotte, NC) Eric Skipper, MD (704-355-4794)
Northwestern University Medical Jon S. Matsumura, MD James S. T. Yao, MD, PhD Mimi Bradley, RN
School (Chicago, Ill) Howard Chrisman, MD (312-908-2714)
Oschner Clinic Samuel R. Money, MD W. Charles Sternberg III, MD Nicole Monard, RN
(New Orleans, La) Moises Voselevitz, MD (504-842-4070)
Washington Hospital Center John Laird, MD Richard J. Gray, MD Debby Deforty, RN
(Washington, DC) Bruce M. Smith, MD (202-877-7452)
Lexington Medical Center William Moore, Jr, MD Terry O. Norton, MD Melody Heffline, RN
(West Columbia, SC) (803-796-8901)
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With three cases of migration in a short-term follow-
up period and the known propensity of the remaining
neck to dilate, do you feel there is any benefit or need for
a more secure attachment of the device to the neck of the
aneurysm as compared with the present device that you
are using?
Finally, with a mortality rate of 2.6% and a total com-
plication rate of 17%, would you recommend the use of
this technique for small aneurysms, especially in the 3-cm
to 4-cm range as allowed in your protocol?
I would like to congratulate the authors on their excel-
lent results in the stent graft repair. There should be no
residual doubt that endovascular repair of aneurysms is
here to stay and that improved results can be expected
with improving technology. I enjoyed your presentation
and the opportunity to review the manuscript, and I thank
the Society for the privilege of discussing it.
Dr Christopher K. Zarins. Thank you, Dr Makaroun,
for your discussion.
With regards to your first question regarding the med-
ical morbidity and mortality rates, in calculating our
results we counted each patient’s outcome according to
the most severe event so that we would not duplicate
counting events. So, if a patient had a major medical com-
plication and died, that patient was counted as a death as
opposed to a major medical complication. Similarly, if a
patient had a major surgical complication and also a med-
ical complication, he was counted as a major surgical com-
plication. The patient in the surgical group with a 74-day
hospital stay had multiple reoperations and multiple med-
ical complications but was counted once as a surgical com-
plication. So, in that you are correct—if we counted each
medical complication individually, the rate would be high-
er in both the stent graft and surgical group. But the over-
all benefit of reduced morbidity in the stent graft group
remains.
You noted that the reoperation rate in the surgical
group was higher than at your institution, and I might add
that it is higher than at my institution as well. However, it
is important to note that this is a multicenter prospective
clinical trial and that such trials generally have outcomes
that are not as good as those reported by single institu-
tions. You may recall that the stroke/death rate for carotid
endarterectomy in the North American Symptomatic
Carotid Endarterectomy Trial and the Asymptomatic
Carotid Atherosclerosis Study were higher than those
found in most large published series of carotid endarterec-
tomy. It is possible that the reoperation rate for stent graft
repair of aneurysms as reported in this trial is also higher
than you experience at your institution. The important
measure in a multicenter trial is the comparison of the end
points between the two study groups. In this study, the
complications were counted in the same manner in both
groups, and clearly there were fewer complications in the
stent graft group.
The endoleak question is an important question. We
obviously need to pay attention to the 9% endoleak rate at
6 months. A significant number of those aneurysms did
become smaller as you noted, and I do not have a ready
explanation. Perhaps it is because the endoleaks are small
as related to lumbar arteries. The outcome and the ulti-
mate significance of those small endoleaks remains to be
determined. Large endoleaks or cases in which the
aneurysm enlarges should be treated promptly. The mod-
ular design of this stent graft system allows the insertion of
proximal and distal extender cuffs to seal junctional leaks.
In response to your question on migration, I should
note that the migrations we observed were never in a lon-
gitudinal direction because of the longitudinal columnar
support in this device. Migrations were in a lateral sense,
such as in the case that I showed. Two were proximal
leaks, and they were corrected with proximal extender
cuffs. I think they were related to short necks and tortu-
ous necks. As we become more skilled at precisely localiz-
ing the stent graft immediately at the renal arteries, per-
haps we will see fewer of these in the future. The third
migration was a result of a low placement of the iliac limbs
in the bifurcation segment junction. This was corrected
with an extender cuff to cover that junction site. So I do
not know whether migration does in fact occur. I share
your concern of possible future dilation of the infrarenal
neck, and this is something that we need to look for and
monitor over time.
As far as the mortality rate and whether we should be
treating small aneurysms is concerned, I will note that the
mortality rate in the 150 patients in phase II was 1.3%. I
think that patients who undergo stent graft repair now
tend to be older and sicker and more frail than we have
seen for open surgical repair. Thus, I am not sure you can
evaluate these devices primarily on the basis of the mor-
tality rate because the mortality rate to a large extent may
be caused by patient comorbidities rather than by the pro-
cedure. With regard to the question of small aneurysms,
we do see patients with small aneurysms who are request-
ing these procedures. Thus far, the data supports their use
for small aneurysms, but clearly more data and longer 
follow-up periods are needed to satisfactorily answer this
question.
Dr Samuel S. Ahn (Los Angeles, Calif). This was an
excellent presentation, and I congratulate you for those
encouraging results. I just have a series of related ques-
tions. One, did you keep track of the patients who were
excluded? If so, how many patients were excluded or what
percentage were excluded? And third, what can we do to
improve the inclusion criteria?
Dr Zarins. We have evaluated a large number of
patients, but we have not specifically tracked patients who
were excluded. I would guess that our overall acceptance
rate is about 50% to 60% of patients who present with
abdominal aortic aneurysms, but it may be higher. We cer-
tainly need to track all patients with aneurysms as you sug-
gest to fully evaluate this procedure.
Dr William J. Quinones-Baldrich (Los Angeles,
Calif). I also want to congratulate you on your excellent
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results and a nice presentation. One of the observations
that has been made recently has been that as aneurysms
shrink in diameter they also shrink in length. In one of the
European society papers, the shortening in length is actu-
ally greater than the change in diameter. My question
relates to the incidence of migration that you observed
and whether or not you feel that this may be related to the
fact that your device is fully supported and may not be able
to accommodate the shrinking in the length of the
aneurysm.
Dr Zarins. You have made a good point that needs to
be carefully studied. In our three cases of migration, we
have seen elongation with the appearance of a late
endoleak rather than shrinkage in length and have cor-
rected the problem with increasing the length with exten-
der cuffs. Your concern, of course, is that if the aneurysm
shrinks in length, it possibly might move the stent graft to
cover a renal artery. We have not encountered this and
have seen no evidence of longitudinal migration.
However, it is something that we will need to watch for
and observe.
Dr Geoffrey M. White (Sydney, Australia). I would
like to ask a brief question about the incidence of primary
endoleaks in this trial. To date, we have used the
Medtronic graft in 23 cases and have documented a 43%
incidence rate of endoleak on contrast enhanced comput-
ed tomographic scans performed before discharge. Most
of these endoleaks appeared to be through small defects in
the graft wall.
You have reported a 21% endoleak rate at discharge,
with a much lower incidence rate of endoleak at 6 months
and 12 months follow-up. Therefore, it would be reason-
able to presume that many of the endoleaks have closed by
a process of thrombosis over the interval of 6 or 12
months of follow-up. I would like to hear your opinion
regarding the safety of a thrombotic seal for closure of an
endoleak through a small defect in the graft wall and your
thoughts concerning the long-term behavior of such
sealed endoleaks.
Dr Zarins. The endoleak rate before discharge was
27% in our experience, and we thought that 10 of those
patients had transgraft flow, which is the occurrence of
small openings in the polyester graft made by the needle
used to suture it to the nitinol stent. Those leaks uniform-
ly seal. I do not think that those will be a problem. I think
that of more concern are persistent leaks related to attach-
ment sites or to branch flow. I do not think that the trans-
graft flow will be a major problem.
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